Modality
ERT
MOA
DLL3 ADC
Target
GPRC5D
Pathway
Fibrosis
RBHuntington'sMM
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
→ Apr 2030
Phase 2Current
NCT04063360
2,103 pts·Huntington's
2020-09→2030-04·Not yet recruiting
2,103 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-184.0y awayPh2 Data· Huntington's
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Not yet…
Catalysts
Ph2 Data
2030-04-18 · 4.0y away
Huntington's
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04063360 | Phase 2 | Huntington's | Not yet recr... | 2103 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| ASN-7408 | Ascendis Pharma | NDA/BLA | GPRC5D | |
| RVM-3746 | Revolution Medicines | Phase 1/2 | GPRC5D |